TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01996384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classical Acupuncture
Description: Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-classical acupuncture
Description: Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
Study: NCT04300413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Rehabilitation plus Mobility (HeRo)
Description: Progressive, high-intensity strengthening and functional intervention coupled with structured mobility based in principals of behavioral economics.
Study: NCT02350374

Intervention type: OTHER
Group type: OTHER
Intervention: carbohydrate counting
Description: patients must fill their logbook with the following data:~* cho amount at breakfast, lunch, snack and dinner~* insulin amount at breakfast, lunch, snack and dinner
Study: NCT01214837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine Vaccines
Description: Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine Vaccines
Description: Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine Vaccines
Description: Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
Study: NCT03671811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: Given PO
Study: NCT01373346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long limb Roux-en Y reconstruction
Description: After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
Study: NCT00979537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nisoldipine Extended-release Tablets, 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sular Tablets, 40 mg
Study: NCT03671811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pterostilbene
Description: Given PO
Study: NCT02178176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education, encouragement, card sort
Description: Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education, encouragement
Description: Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
Study: NCT03922035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard peri-/post-transplant supportive care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard peri-/post-transplant supportive care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum CBM 588 Probiotic Strain
Description: Given PO
Study: NCT00854178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of two anesthetic drugs
Description: Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
Study: NCT00819585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.
Study: NCT03644329

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The volunteers will not performed the interventions.
Study: NCT00819585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg capsule orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5 mg capsule orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5 mg capsule orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.
Study: NCT03644329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower-load resistance training (LL)
Description: The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher-load resistance training (HL)
Description: The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher-volume resistance training (HV)
Description: The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
Study: NCT00819585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Canakinumab
Description: Subcutaneous injection.
Study: NCT00441636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure (CPAP)
Description: CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
Study: NCT00566124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: 0.4 U/kg bw insulin detemir injected s.c. in the thigh.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: 0.4 U/kg bw insulin glargine injected s.c. in the thigh

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulatard
Description: 0.4 U/kg bw NPH insulin injected s.c. in the thigh
Study: NCT03238391

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ischemic preconditioning
Description: It is mentioned before in arm/group descriptions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: It is mentioned before in arm/group descriptions
Study: NCT01759771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4,000 IU of VD3 for at least one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for at least one year
Study: NCT04329364

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Laser Haemorrhoidoplasty (LAH)
Description: Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open milligan-morgan conventional haemorrhoidectomy
Description: conventional excisional haemorrhoidectomy
Study: NCT04346732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Description: Vapocoolant spray
Study: NCT00206375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Growth hormone + Synthroid + Lupron
Study: NCT00819585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Canakinumab
Description: Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Canakinumab
Description: Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Canakinumab
Description: Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Canakinumab
Description: Subcutaneous injection.
Study: NCT00206375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment and puberty
Description: Lupron once a month and growth hormone daily
Study: NCT04200365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib will be administered orally once daily for up to 24 months.
Study: NCT03947684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Device
Description: The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
Study: NCT00819585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Matching Canakinumab
Description: Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Colchicine
Description: Capsule orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Colchicine
Description: Capsule orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Colchicine
Description: Capsule orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Colchicine
Description: Capsule orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Colchicine
Description: Capsule orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Colchicine
Description: Capsule orally once daily for 16 weeks.
Study: NCT04621669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: 0.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin calcium
Description: 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: 500 mg
Study: NCT01632735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Continuing Care
Description: Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
Study: NCT01824173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase in the levels of plasma amino acids
Description: Aminosyn 15%; 160 mg/kg FFM/h for 4 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase in the levels of plasma amino acids
Description: Aminosyn 15%; 160 mg/kg FFM/h for 4 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate intensity for 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate intensity for 45 minutes
Study: NCT00970528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay, BAYG5421)
Description: uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose (Basen)
Description: uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
Study: NCT01361945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
Study: NCT04995471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In presence RRT - prototype software
Description: Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
Study: NCT02840006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia only
Description: Induction drugs: Citrate of fentanyl, atracurium, etomidate
Study: NCT04995471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In presence RRT - online platform
Description: RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-RRT - prototype software
Description: Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-RRT - online platform
Description: RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available.
Study: NCT00907582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic cell transplantation
Description: Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3.
Study: NCT01899859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR-MD-02
Description: GR-MD-02; galactoarabino-rhamnogalaturonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR-MD-02
Description: GR-MD-02; galactoarabino-rhamnogalaturonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR-MD-02
Description: GR-MD-02; galactoarabino-rhamnogalaturonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: GR-MD-02 Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: GR-MD-02 Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: GR-MD-02 Placebo
Study: NCT03811717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST+EX
Description: Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST+EX
Description: Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST
Description: Participants will complete an 8-hour fast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST
Description: Participants will complete an 8-hour fast.
Study: NCT02840006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia and Spinal anesthesia
Description: Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
Study: NCT04426500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Direct injection of 0.25% bupivacaine into surgical wounds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: Direct injection of 0.25% bupivacaine into surgical wounds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Direct injection of 0.25% bupivacaine into surgical wounds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided transversus abdominus plane block
Description: bilateral TAP using ultrasound guidance in prostatectomies
Study: NCT04174196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Participants will be treated with CC-486 and lenalidomide for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will be treated with CC-486 and lenalidomide for 6 cycles
Study: NCT01906866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Circadin 2/5/10 mg
Description: Circadin 2/5/10 mg. Active arm
Study: NCT04174196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be initiated to the plasmacytoma after cycle 2
Study: NCT00840333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin solution for Inhalation)
Description: DOSE BASED ON PATIENTS WEIGHT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin solution for Inhalation)
Description: DOSE BASED ON PATIENTS WEIGHT
Study: NCT01906866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study: NCT00692510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsule, oral, dose once daily, 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, oral, dose once daily, 7 days